Adicet Bio Inc (ACET)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.92-5.81%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ACET
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -60.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ACET — litigation filed
Dated 2026-09-28
Other Events. On September 28, 2026, the Company announced preliminary data from its Prula-cel Phase 1 study in patients with SLE with or without LN. The preliminary data, as well as additional corporate updates, are summarized below. Prula-cel Phase 1 Study Data Data highlights as of the August 28, 2026 cut-off date were as follows: • 22 patients (16 LN and 6 extra renal SLE) were evaluated with follow-up ranging from 6-21 months. • Efficacy endpoints. Prula-cel treatment yielded high rates…
Why it matters: The Phase 1 results showed 12-month responses, but larger studies must test if they last. A weaker follow-up could challenge the early signal.
Supportive ifThe mid-2027 LN/SLE update shows responses lasting 12 months. These include complete renal response and DORIS remission.
Worry ifThe mid-2027 update shows that prior 12-month responses were lost or that key response rates fell materially.
Why it matters: Starting the lupus nephritis trial would move prula-cel from Phase 1 toward a pivotal test. A delay would weaken the stated timeline.
Supportive ifAdicet reports that start-up for the pivotal trial began in 4Q 2026. It names the planned study group.
Worry ifBy the end of 4Q 2026, Adicet reports no start-up activity or a delay beyond 2026.
Why it matters: Adicet reported $118.2 million in cash and said it could fund operations into 2H 2027. A shorter runway could raise funding pressure.
Worry ifA quarterly update keeps the stated cash runway at least through 2H 2027, without new financing needs disclosed.
Less concerning ifAdicet reports its cash will not fund operations into 2H 2027. Or, it announces funding to extend its runway.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$223 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $763 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,193 loss on $10,000 · 71.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.